Chapter 13: Role of kynurenine pathway in insulin resistance: Toward kynurenine hypothesis of insulin resistance and diabetes

Targeting the Broadly Pathogenic Kynurenine Pathway

Volumn , Issue , 2015, Pages 169-178

  Oxenkrug, Gregory F ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Infl ammation; Insulin resistance; Stress; Xanthurenic acid

Indexed keywords

EID: 84956975118     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-11870-3_13     Document Type: Chapter

References (68)

1. Kotake Y, Ueda T, Mori T, Igaki S, Hattori M. Abnormal tryptophan metabolism and experimental diabetes by xanthurenic acid (XA). Acta Vitaminol Enzymol. 1975;29(1-6):236-9.
2. Connick LH, Stone TW. The role of kynurenines in diabetes mellitus. Med Hypotheses. 1985;18(4):371-6.
3. Oxenkrug G. Insulin resistance and dysregulation of tryptophan-kynurenine and kynureninenicotinamide adenine dinucleotide metabolic pathways. Mol Neurobiol. 2013;48:294-301. doi: 10.1007/s12035-013-8497-4.
4. Oxenkrug G, Ratner R, Summergrad P. Kynurenines and vitamin B6: link between diabetes and depression. J Bioinform Diabetes. 2013;1:1-10.
5. Gragnoli C. Hypothesis of the neuroendocrine cortisol pathway gene role in the comorbidity of depression, type 2 diabetes, and metabolic syndrome. Appl Clin Genet. 2014;7:43-53. doi: 10.2147/TACG.S39993.
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
7. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-46.
8. Rosmond R. Stress induced disturbances of the HPA axis: a pathway to Type 2 diabetes? Med Sci Monit. 2003;9(2):RA35-9.
9. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812-17.
10. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465-77.
11. Han Q, Fang J, Li J. 3-Hydroxykynurenine transaminase identity with alanine glyoxylate transaminase. A probable detoxification protein in Aedes aegypti. J Biol Chem. 2002;277(18):15781-7.
12. Alberati-Giani D, Ricciardi-Castagnoli P, Kohler C, Cesura AM. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem. 1996;66(3):996-1004.
13. Pawlak D, Takada Y, Urano T, Takada A. Serotonergic and kynurenic pathways in rats exposed to foot shock. Brain Res Bull. 2000;52(3):197-2012.
14. Hayaishi O. Properties and function of indoleamine 2,3-dioxygenase. J Biochem. 1976;79(4):13p-21p.
15. Christen S, Peterhans E, Stocker R. Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. Proc Natl Acad Sci U S A. 1990; 87(7):2506-10.
16. Paul L, Ueland PM, Selhub J. Mechanistic perspective on the relationship between pyridoxal 5'-phosphate and inflammation. Nutr Rev. 2013;71(4):239-44.
17. van de Kamp JL, Smolen A. Response of kynurenine pathway enzymes to pregnancy and dietary level of vitamin B-6. Pharmacol Biochem Behav. 1995;51(4):753-8.
18. Allegri G, Zaccarin D, Ragazzi E, Froldi G, Bertazzo A, Costa CV. Metabolism of tryptophan along the kynurenine pathway in alloxan diabetic rabbits. Adv Exp Med Biol. 2003;527:387-93.
19. Ciorba MA. Kynurenine pathway metabolites: relevant to vitamin B-6 deficiency and beyond. Am J Clin Nutr. 2013;98(4):863-4.
20. Ogasawara N, Hagino Y, Kotake Y. Kynurenine-transaminase, kynureninase and the increase of xanthurenic acid excretion. J Biochem. 1962;52:162-6.
21. Rios-Avila L, Nijhout HF, Reed MC, Sitren HS, Gregory 3rd JF. A mathematical model of tryptophan metabolism via the kynurenine pathway provides insights into the effects of vitamin B-6 deficiency, tryptophan loading, and induction of tryptophan 2,3-dioxygenase on tryptophan metabolites. J Nutr. 2013;143(9):1509-19.
22. Okamoto H. Recent advances in physiological and pathological significance of tryptophan- NAD+ metabolites: lessons from insulin-producing pancreatic beta-cells. Adv Exp Med Biol. 2003;527:243-52.
23. Rudzite V, Fuchs D, Kalnins U, Jurika E, Silava A, Erglis A, et al. Prognostic value of tryptophan load test followed by serum kynurenine determination. Its comparison with pyridoxal-5- phosphate, kynurenine, homocysteine and neopterin amounts. Adv Exp Med Biol. 2003;527:307-15.
24. Yess N, Price JM, Brown RR, Swan PB, Linkswiler H. Vitamin B6 depletion in man: urinary excretion of tryptophan metabolites. J Nutr. 1964;84:229-36.
25. Musajo L. Old and new fields of research on the tryptophan. Acta Vitaminol Enzymol. 1975;29(1-6):1-3.
26. Lepkovsky S, Roboz E, Haagen-Smit AJ. Xanthurenic acid and its role in the tryptophane metabolism of pyridoxine-deficient rats. J Biol Chem. 1943;149:195-201.
27. Greenberg LD, Bohr DF, et al. Xanthurenic acid excretion in the human subject on a pyridoxinedefi cient diet. Arch Biochem. 1949;21(1):237-9.
28. Greenberg LD, Rinehart JF. Xanthurenic acid excretion in pyridoxine deficient rhesus monkeys. Fed Proc. 1948;7(1 Pt 1):157.
29. Hattori M, Kotake Y. Studies on the urinary excretion of xanthurenic acid in diabetics. Acta Vitaminol Enzymol. 1984;6(3):221-8.
30. Ikeda S, Kotake Y. Urinary excretion of xanthurenic acid and zinc in diabetes: (3). Occurrence of xanthurenic acid-Zn2+ complex in urine of diabetic patients and of experimentally-diabetic rats. Ital J Biochem. 1986;35(4):232-41.
31. Gu H, Chen H, Pan Z, Jackson AU, Talaty N, Xi B, et al. Monitoring diet effects via biofluids and their implications for metabolomics studies. Anal Chem. 2007;79(1):89-97.
32. Masiello P, Balestreri E, Bacciola D, et al. Influence of experimental diabetes on brain levels of monoamine neurotransmitters and their precursor amino acids during tryptophan loading. Acta Diabetol Lat. 1987;24:43-50.
33. Koopmans SJ, Ruis M, Dekker R, et al. Surplus dietary tryptophan inhibits stress hormone kinetics and induces insulin resistance in pigs. Physiol Behav. 2009;98:402-10.
34. Manusadzhian VG, Kniazev A, Vakhrusheva LL. Mass spectrometric identification of xanthurenic acid in pre-diabetes. Vopr Med Khim. 1974;20(1):95-7.
35. Munipally PK, Agraharm SG, Valavala VK, et al. Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch Physiol Biochem. 2011;117:254-8.
36. Koenig P, Nagl C, Neurauter G, Schennach H, Brandacher G, Fuchs D. Enhanced degradation of tryptophan in patients on hemodialysis. Clin Nephrol. 2010;74(6):465-70.
37. Calandra P. Identification of tryptophan metabolites in the healthy epidermis of diabetics. Acta Diabetol Lat. 1977;14(1-2):26-37.
38. Shen J, Lai CQ, Mattei J, Ordovas JM, Tucker KL. Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study. Am J Clin Nutr. 2010;91(2):337-42.
39. Campbell BM, Charych E, Lee AW, Möller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci. 2014;8:12. doi: 10.3389/fnins.2014.00012.
40. Cazzulo CL, Mangoni A, Mascherpa G. Tryptophan metabolism in affective psychoses. Br J Psychiatry. 1974;112:157-62.
41. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, et al. Prevalence of insulin resistance in metabolic disorders. The Bruneck Study. Diabetes. 1998;47:1643-9.
42. Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol. 2006; 12(44):7075-80.
43. Shlomai M, Mouler E, Rechtma G, et al. The metabolic regulator PGC-1a links hepatitis C virus infection to hepatic insulin resistance. J Hepatol. 2012;57(3):867-73.
44. Lecube C, Hernández J, Genescà J, et al. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care. 2006;29(5):1096-101.
45. Larrea E, Riezu-Boj JI, Gil-Guerrero L, et al. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol. 2007;81(7):3662-6.
46. Higashitani K, Kanto T, Kuroda S, et al. Association of enhanced activity of indoleamine 2, 3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection. J Gastroenterol. 2013;48(5):660-70.
47. Oxenkrug GF, Turski WA, Zgrajka W, Weinstock JV, Summergrad P. Tryptophan-kynurenine metabolism and insulin resistance in hepatitis C patients. Hepat Res Treat 2013;2013:4p. Article ID 149247.
48. Fuchs D, Avanzas P, Arroyo-Espliguero R, Jenny M, Consuegra-Sanchez L, Kaski JC. The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr Med Chem. 2009;16(35):4644-53.
49. Fuchs D, Norkrans G, Wejstal R, Reibnegger G, Weiss G, Weiland O, et al. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b. Eur J Med. 1992;1(4):196-200.
50. Midttun O, Ulvik A, Ringdal-Pedersen E, Ebbing M, Bleie O, Schartum-Hansen H, et al. Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. J Nutr. 2011;141(4):611-17.
51. Spencer ME, Jain A, Matteini A, Beamer BA, Wang NY, Leng SX, et al. Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat. J Gerontol A Biol Sci Med Sci. 2010;65(8):858-65.
52. Oxenkrug G, Tucker KL, Requintina P, Summergrad P. Neopterin, a marker of interferongamma- inducible inflammation, correlates with pyridoxal-5'-phosphate, waist circumference, HDL-cholesterol, insulin resistance and mortality risk in adult Boston community dwellers of Puerto Rican origin. Am J Neuroprot Neuroregen. 2011;3(1):48-52.
53. Theofylaktopoulou D, Middtun O, Ulvik A, et al. A community-based study of determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin Exp Immunol. 2013;173:121-30.
54. Malina HZ, Richter C, Mehl M, Hess OM. Pathological apoptosis by xanthurenic acid, a tryptophan metabolite: activation of cell caspases but not cytoskeleton breakdown. BMC Physiol. 2001;1:7.
55. Meyramov G, Korchin V, Kocheryzkina N. Diabetogenic activity of xanturenic acid determined by its chelating properties? Transplant Proc. 1998;30(6):2682-4.
56. Noto Y, Okamoto H. Inhibition by kynurenine metabolites of proinsulin synthesis in isolated pancreatic islets. Acta Diabetol Lat. 1978;15(5-6):273-82.
57. Rogers KS, Evangelista SJ. 3-Hydroxykynurenine, 3-hydroxyanthranilic acid, and o- aminophenol inhibit leucine-stimulated insulin release from rat pancreatic islets. Proc Soc Exp Biol Med. 1985;178(2):275-8.
58. Shibata Y, Ohta T, Nakatsuka M, Ishizu H, Matsuda Y, Shindo T, et al. Taurine and kynureninase. Adv Exp Med Biol. 1996;403:55-8.
59. Takeuchi F, Tsubouchi R, Shibata Y. Effect of tryptophan metabolites on the activities of rat liver pyridoxal kinase and pyridoxamine 5-phosphate oxidase in vitro. Biochem J. 1985;227(2):537-44.
60. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5(11):2516-22.
61. Liu D, Pavlovic D, Chen MC, Flodstrom M, Sandler S, Eizirik DL. Cytokines induce apoptosis in beta-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS-/-). Diabetes. 2000;49(7):1116-22.
62. Sarkar SA, Wong R, Hackl SI, Moua O, Gill RG, Wiseman A, et al. Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes. 2007;56(1):72-9.
63. Eizirik DL, Sandler S, Welsh N, Cetkovic-Cvrlje M, Nieman A, Geller DA, et al. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest. 1994;93(5):1968-74.
64. Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med. 2014;2014:289264.
65. Cukras CA, Petrou P, Chew EY, Meyerle CB, Wong WT. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci. 2012;53(7):3865-74.
66. Yu CJ, Zheng MF, Henry CJ, Huang Y, Wynne A, Hanke M, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation. 2008;5:15.
67. Yu CJ, Zheng MF, Kuang CX, Huang WD, Yang Q. Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2,3-dioxygenase activity in vitro. J Alzheimers Dis. 2010;22(1):257-66.
68. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation. 2008;5:15.